Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06626516 · ClinicalTrials.gov registry record · Phase 1

Tebentafusp-tebn With LDT in Metastatic UM

A Phase 1 study of Metastatic Uveal Melanoma, sponsored by Thomas Jefferson University.

Recruiting
Registry status
Phase 1
Development phase
109
Enrollment target
1
Study location

NCT06626516 is a Phase 1 study of Metastatic Uveal Melanoma that is actively recruiting participants, run by Thomas Jefferson University. The registered enrollment target is 109 participants, below the 125-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06626516, a Phase 1 study of Metastatic Uveal Melanoma, is actively recruiting participants, sponsored by Thomas Jefferson University.

RECRUITING
Registry status
Phase 1
Development phase
109 participants
Enrollment target
1
Study location

Study Summary

This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate the safety and efficacy of tebentafusp-tebn in combination with hepatic IE in patients with a low to moderate hepatic disease burden. In Part 2, the study will investigate the efficacy of tebentafusp-tebn in combination with TACE in patients with bulky hepatic disease.

Conditions Studied

Metastatic Uveal Melanoma

Interventions

  • DRUG BCNU
  • DRUG Tebentafusp-Tebn
  • DRUG GM-CSF (Sargramostim)

Study Locations (1)

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 109 participants
Start Date 2025-10-15
Est. Completion 2032-08
Phase Phase 1

Sponsor

Thomas Jefferson University

292 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06626516

The ClinicalTrials.gov registry entry for NCT06626516 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 125-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (13% lower). The listed sponsor is Thomas Jefferson University, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which BCNU is the first listed.

NCT06626516 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT06626516 about?

NCT06626516 is a clinical study titled "Tebentafusp-tebn With LDT in Metastatic UM". This study is a multicenter, open label phase I/ II trial to assess the safety and clinical efficacy of tebentafusp-tebn in combination with liver-directed therapies in HLA-A\*0201 positive patients with metastatic uveal melanoma. In Part 1 of the study, the Prinicipal Investigator will investigate ...

What is the current status of trial NCT06626516?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 109 participants. The study started on 2025-10-15. Estimated completion is 2032-08.

What conditions does trial NCT06626516 study?

This clinical trial studies the following conditions: Metastatic Uveal Melanoma.

What interventions are being tested in trial NCT06626516?

The interventions under investigation include: BCNU (DRUG), Tebentafusp-Tebn (DRUG), GM-CSF (Sargramostim) (DRUG).

Who is sponsoring clinical trial NCT06626516?

This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06626516 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Uveal Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Uveal Melanoma

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.